Results: CagriSema: 23.0% average weight loss Tirzepatide: 25.5% average weight loss CagriSema did not meet the non-inferiority threshold tirzepatide won by 2.5 percentage points This is a meaningful result
Nevertheless, despite a wealth of clinical data, there is still a lack of literature that combines demand-side dynamics, product positioning, and marketing strategy to explain such blockbuster success
During the GHK-CU adjustment period, you might pause retinol entirely to reduce variables
Your dose may increase during your treatment, but your monthly price remains flatno surprise price jumps as you adjust to your effective dose
With consistent use, appropriate lifestyle support, and realistic expectations, GLP-1 therapy can play a significant role in long-term weight management.
In fact, in the United States, 1 in 3 adults is overweight (defined as a body mass index, or BMI, between 25 and 25.99), and two in five are obese (defined as a BMI over 30)
